Work

Adjunctive Oral Tacrolimus following fulguration in Hunner’s lesion bladder pain syndrome/ Interstitial cystitis: A Pilot Study

Year: 2026
Type: preprint
Study design: Clinical Trial
Abstract: Introduction and Hypothesis: Hunner’s lesion disease is increasingly recognised as a distinct phenotype of bladder pain syndrome/interstitial cystitis (BPS/IC). Given the immune-mediated pathways implicated in its pathogenesis, we hypothesised that adjunctive oral tacrolimus following fulguration may improve symptoms in patients with Hunner’s lesion BPS/IC. Methods In this single-centre prospective pilot study, twelve patients with cystoscopically confirmed Hunner’s lesions received oral tacrolimus (0.04 mg/kg/day) for 10 weeks following standard fulguration. Symptoms were assessed using the validated Apollo clinical scoring system (ACS) at baseline and at 4, 8, and 12 weeks, and 6 months. Tacrolimus trough levels and biochemical safety parameters were monitored serially. Results The median baseline scores were 16/20 for pain, 8/10 for nocturia, 4/5 for urgency, 4/5 for frequency, 4/5 for psychosocial impact, and 37/50 for the overall ACS. Significant improvements in the median overall ACS and all symptom domains were observed at 4, 8, and 12 weeks compared with baseline (p < 0.001). Improvements in the overall ACS and non-pain domains was sustained at 6 months, whereas pain scores no longer differed significantly from baseline (p = 0.067). All patients demonstrated clinically meaningful reduction in ACS, with excellent clinical response (ACS reduction > 30 points) observed in four patients at 4 weeks, and one patient at 6 months. Tacrolimus was generally well tolerated. Mild dyspepsia was the most common adverse event. One patient developed a urinary tract infection responsive to antibiotics, and no clinically significant biochemical toxicities were observed. Conclusion Adjunctive oral tacrolimus following fulguration demonstrated encouraging preliminary signals of clinical benefit with an acceptable safety profile in Hunner’s lesion BPS/IC. Controlled studies are required to determine its incremental efficacy and long-term safety.
Language: English
Subfield: Urology
Field: Medicine
Open Access status: green
OpenAlex ID: W7236556086
Cites: 24
Cited by:
Related to: 10